GB stock · Healthcare sector · Drug Manufacturers—General
Company Logo

AstraZeneca PLC

AZNNASDAQ

54.84

USD
-0.07
(-0.13%)
Market Closed
-161.90P/E
15Forward P/E
-8.08P/E to S&P500
180.800BMarket CAP
5.28%Div Yield
Upcoming Earnings
- -
Shares Short
9/15/22
6.42M
Short % of Float
- -
Short % of Shares Outs.
0.21%
% Held by Insiders
0.05%
% Held by Institutions
18.29%
Beta
0.13
PEG Ratio
1.16
52w. high/low
71.70/52.65
Avg. Daily Volume
6.52M
Return %
Stock
S&P 500
1 year
(8.85)
(16.20)
3 years
22.46
22.35
5 years
62.70
44.82
Scale: |
High
Low
29.74
21.11
24.92
16.29
23.80
14.98
26.76
20.15
26.27
20.45
24.64
19.86
29.83
22.23
41.34
29.14
36.69
29.50
35.04
25.55
35.60
26.51
41.78
32.69
51.23
35.30
64.94
36.15
64.21
46.48
71.70
52.65
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
8.46
9.89
10.87
11.33
11.57
12.34
11.09
10.27
10.34
9.77
9.09
8.87
8.72
9.37
10.14
14.26
14.06
Earnings per share
1.93
1.87
2.10
2.60
2.80
3.67
2.50
1.02
0.49
1.12
1.38
1.19
0.85
0.51
1.22
0.04
(0.33)
FCF per share
2.03
1.95
1.62
3.03
2.96
2.40
0.92
2.13
1.71
0.21
0.72
0.77
0.49
0.20
0.84
1.43
1.75
Dividends per share
0.71
0.88
0.94
1.03
1.17
1.38
1.45
1.38
1.40
1.38
1.41
1.39
1.37
1.38
1.36
1.47
1.48
CAPEX per share
0.43
0.56
1.39
1.02
0.76
0.48
1.83
0.82
1.09
1.10
0.91
0.64
0.54
0.95
0.99
0.84
0.71
Book Value per sh.
4.89
4.94
5.48
7.13
8.07
8.54
9.41
9.27
7.78
7.31
5.87
5.91
4.92
5.04
5.95
14.96
11.10
Comm.Shares outs.
3,128
2,990
2,906
2,896
2,876
2,722
2,522
2,504
2,524
2,528
2,530
2,532
2,534
2,602
2,624
2,624
2,951
Avg. annual P/E ratio
14.4
13.9
10.0
8.0
8.5
6.5
9.2
24.9
72.4
30.0
21.8
26.6
43.4
82.8
42.6
1,302.4
(161.9)
P/E to S&P500
0.8
0.8
0.5
0.1
0.4
0.4
0.6
1.5
4.0
1.5
1.0
1.1
1.7
3.4
1.1
43.4
(8.1)
Avg. annual div. yield
2.5%
3.4%
4.5%
5.0%
4.9%
5.8%
6.3%
5.4%
3.9%
4.1%
4.7%
4.4%
3.7%
3.3%
2.6%
2.6%
2.4%
Revenue (m)
26,475
29,559
31,601
32,804
33,269
33,591
27,973
25,711
26,095
24,708
23,002
22,465
22,090
24,384
26,617
37,417
41,487
Operating margin
31.0%
27.4%
28.9%
35.2%
34.5%
38.1%
29.1%
14.4%
8.2%
16.7%
21.3%
16.4%
15.3%
12.0%
19.4%
2.8%
0.5%
Depreciation (m)
1,345
1,856
2,620
2,087
2,741
2,550
2,518
4,583
3,282
2,852
2,357
3,036
3,753
3,762
3,149
6,530
7,042
Net profit (m)
6,043
5,595
6,101
7,521
8,053
9,983
6,297
2,556
1,233
2,825
3,499
3,001
2,155
1,335
3,196
112
(1,063)
Income tax rate
29.0%
29.5%
29.4%
30.2%
26.4%
19.0%
18.0%
21.3%
0.9%
7.9%
4.1%
(28.8)%
(2.9)%
20.7%
19.7%
143.4%
30.2%
Net profit margin
22.8%
18.9%
19.3%
22.9%
24.2%
29.7%
22.5%
9.9%
4.7%
11.4%
15.2%
13.4%
9.8%
5.5%
12.0%
0.3%
(2.4)%
Working capital (m)
7,489
1,895
2,832
6,120
8,344
7,754
5,145
4,284
(633)
1,138
(1,994)
(3,233)
(701)
(2,554)
(763)
3,650
(93)
Long-term debt (m)
1,087
10,876
10,855
244
9,097
7,338
9,409
8,516
8,337
14,109
14,495
15,560
17,359
15,730
17,505
28,888
28,805
Equity (m)
15,304
14,778
15,912
20,660
23,213
23,246
23,737
23,224
19,627
18,490
14,854
14,960
12,468
13,127
15,622
39,268
36,340
ROIC
31.6%
19.5%
21.1%
22.5%
22.5%
29.3%
17.9%
7.4%
5.3%
8.4%
10.6%
8.7%
8.3%
5.8%
9.1%
(0.5)%
(0.0)%
Return on capital
30.5%
18.9%
21.4%
21.9%
21.4%
25.3%
16.2%
6.7%
3.8%
6.8%
8.3%
5.0%
5.9%
5.1%
7.9%
1.0%
(0.0)%
Return on equity
39.5%
37.9%
38.3%
36.4%
34.7%
42.9%
26.5%
11.0%
6.3%
15.3%
23.6%
20.1%
17.3%
10.2%
20.5%
0.3%
(2.9)%
Plowback ratio
63.3%
52.8%
55.1%
60.4%
58.3%
62.3%
41.8%
(35.4)%
(185.6)%
(23.4)%
(1.8)%
(17.3)%
(61.7)%
(169.1)%
(11.8)%
(3,342.9)%
510.0%
Div.&Repurch./FCF
84.7%
113.1%
67.8%
32.4%
64.4%
143.6%
252.1%
55.8%
75.3%
642.4%
191.9%
177.5%
276.7%
13.2%
161.5%
101.7%
- -
Capital Structure
31 Mar · 2022 | Q1
All numbers in millions
Total liabilities
$ 63,914
Total assets
$ 100,273
Long-term debt
$ 28,805
Cash and equiv.
$ 5,762
Goodwill
$ 19,963
Retained earnings
$ (1,228)
Common stock
3,094
Enterprise Value
$ 203,843
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
6,180
7,950
6,398
Receivables
- -
- -
- -
Inventory
3,193
4,024
8,983
Other
6,190
10,033
11,823
Current assets
15,563
19,544
26,244
Acc. Payable
1,774
2,350
2,824
Debt due
2,010
2,386
1,893
Other
14,333
15,571
17,877
Current liabilities
18,117
20,307
22,594
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
40.58%
14.61%
4.14%
Cash flow
71.59%
76.74%
64.21%
Earnings
(96.50)%
(5.83)%
0.47%
Dividends
7.95%
2.37%
0.63%
Book value
151.36%
39.75%
12.96%
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
6,354
6,275
6,578
7,410
26,617
2021
7,320
8,220
9,866
12,011
37,417
2022
11,390
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.30
0.29
0.25
0.39
1.22
2021
0.59
0.21
(0.63)
(0.13)
0.04
2022
0.12
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.91
- -
0.45
- -
1.36
2021
0.94
- -
0.53
- -
1.47
2022
0.96
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. Pascal Soriot M.B.A.
Full-time employees:
83,100
City:
Cambridge
Address:
1 Francis Crick Avenue
IPO:
Aug 29, 2001
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.